Several studies have suggested associations between MDM2 (mouse double minute 2 homolog) polymorphisms and leukemia risk, but they reported contradictory results. For better understanding of the effect of MDM2 T309G polymorphism on leukemia risk, we performed a meta-analysis. All eligible studies were identified through a search of PubMed, Web of Science, EMBASE, and Chinese Biomedical Literature (CBM) databases before May 2014. Assessment of associations between the MDM2 T309G polymorphism and leukemia risk was conducted by odds ratios (ORs) and 95% confidence intervals (95% CIs). Finally, a total of 11 publications covering 12 case-control studies with 2, 362 cases and 5, 562 controls concerning MDM2 T309G polymorphism with respect to leukemia were included in the meta-analysis. Significant associations were found between MDM2 T309G polymorphism and leukemia risk in four models in overall populations (G vs T: OR=1.29, 95% CI=1.11-1.49, p=0.001; GG vs TT: OR=1.67, 95% CI=1.21-2.30, p=0.002; GG vs TG/TT: OR=1.56, 95% CI=1.21-2.00, p=0.001; GG/TG vs TT: OR=1.28, 95% CI=1.05-1.57, p=0.015). In the sub-group analysis according to ethnicity, increased leukemia risks were observed in three genetic models among Asians but not Caucasians. In conclusion, the results of our meta-analysis suggest that the MDM2 T309G polymorphism can increase the risk of leukemia, especially among Asian populations.
Introduction
Leukemia is a common malignant disease of hematopoietic systems, it is a malignant tumor of the hematopoietic system and cause by unbalanced hematopoietic cells proliferation and death, uncontrolled differentiation disorder, disruption and other mechanisms of apoptosis in the bone marrow and other hematopoietic tissues proliferate accumulation and infiltration of other tissues and organ (Estey, 2001; Jiang et al., 2014; . Based on the speed of disease progression, leukemia can be divided into acute leukemia and chronic leukemia, while acute leukemia can be subdivided into acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) according to cytogenetic analysis , then chronic leukemia can be divide into chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) (Jiang et al., 2014) . Although previous researches suggest that radiation, smoking, obesity and exposure to chemical carcinogens are considered to be risk factors (Finch, 2007; Bjork et al., 2009; Lichtman, 2010) , the pathogenesis of leukemia is still not fully clarified (Yalcin et al., 2009) . However, only a small proportion of people exposed to these environment Yu-Lan Yan, Feng Han, Wen-Min Tan, Cui-Ping Wu, Xi Qin* and lifestyle risk factors developed leukemia, indicating that the host genetic factors might play an important role in the genesis of leukemia (Ross, 2008; Mullighan, 2010) .
The mouse double minute 2 homolog (MDM2), which is a key negative regulator of the P53 tumor suppressor pathway, has been mapped to chromosome 12q13-14 (Picksley and Lane, 1993; . The MDM2 protein plays a critical role in the regulation of p53 protein stability and functional, it regulates p53 activity through a negative feedback loop (Poyurovsky et al., 2010) . A functional single nucleotide polymorphism (SNP) in the promoter region of MDM2, SNP T309G (rs2279744), was reported to affect MDM2 expression levels. Individuals who carrying the GG genotype of the MDM2 SNP309 polymorphism were found to increase MDM2 expression and thereby attenuates p53 activity (Bond et al., 2004; Qin et al., 2013) . The polymorphism of MDM2 T309G is suggested to be associated with the risk of various human cancers Gao et al., 2014; Tang et al., 2014; Wang et al., 2014) . However, results concerning the relationship between MDM2 T309G polymorphism and leukemia risk were different or even contradictory (Ellis et al., 2008; Phang et al., 2008; Zenz et al., 2008; Chen et al., 2009; Yu-Lan Yan et al Do et al., 2009; Xiong et al., 2009; Phillips et al., 2010; Dong et al., 2012; Ebid et al., 2012; Chen et al., 2013; Liu et al., 2013) . To derive a more precise estimation of the associations between the MDM2 T309G polymorphism and leukemia risk, we performed a meta-analysis of all available studies.
Materials and Methods

Search strategy
We conducted an extensive search to identify all available studies on the association between the MDM2 SNP309 polymorphism and leukemia risk in PubMed, Web of Science, EMBASE, and Chinese Biomedical Literature (CBM) databases up to May 01, 2014, using the following search strategy: ("leukemia" or "hematology" or "malignancy" or "neoplasm" or "cancer") and ("MDM2" or "Murine double minute 2") and ("polymorphism" or "polymorphisms" or "mutation" or "mutations" or "SNP"). There was no restriction on time period, sample size, population, language, or type of report. All eligible studies were retrieved and their references were manual checked to find more relevant articles.
Inclusion and exclusion criteria
Studies included in the meta-analysis were required to match the following criteria: (1) case-control study; (2) study evaluating the association between MDM2 SNP309 polymorphism and leukemia risk; (3) article provided sufficient data to estimate an odds ratio (OR) and 95% confidence interval (95% CI); (4) the control population did not contain malignant tumor patients. The following exclusion criteria were used for excluding studies: (1) not a case-control study; (2) the source of cases and controls, and other essential information were not provided; (3) reviews or reports; (4) only recruited the latest study if more than one studies from the same group occurred.
Data extraction
All the data were carefully extracted by two authors independently from all eligible publications according to the inclusion and exclusion criteria listed above. When encountered the conflicting evaluations, an agreement was reached following a discussion, if could not reached agreement, then a third author was consulted to resolve the debate. The following information was extracted from the included studies: name of first author; year of publication; country of origin; ethnicity of the population; genotyping methods; source of the control group; the types of leukemia and the distribution of genotypes of cases and controls. Different ethnicities were categorized as Asian and Caucasians, while different types of leukemia were categorized as AML, ALL, CML and CLL.
Statistical analysis
The Hardy-Weinberg equilibrium of controls for each study was tested by using a professional web-based program, p>0.05 suggests the controls was followed HWE balance. The pooled odds ratios (OR) with 95% confidence intervals (95% CI) were calculated to assess the strength of the association between the MDM2 T309G polymorphism and leukemia risk according to allele contrast (G vs T), homozygote (GG vs TT), heterozygote (TG vs TT), recessive (GG vs TG/TT), and dominant (GG/ TG vs TT) models. The significance of the summary OR was determined with a Z-test and p<0.05 was considered as statistically significant.
The between-study heterogeneity was texted by using a Chi-square based Q statistic test. Heterogeneity was considered significant when p<0.10, and the random effects model was used to pool the results (DerSimonian and Laird method) (DerSimonian and Laird, 1986) . Otherwise, the fixed-effects model (the Mantel-Haenszel method) was used (Mantel and Haenszel, 1959) . Moreover, we also used I 2 value to test the effect of heterogeneity (Higgins and Thompson, 2002) . If obvious heterogeneity was existed (I 2 value >50% or p<0.10), the overall estimate of risk was calculated by the random-effects model; If obvious heterogeneity was absent (I 2 value <50% or p>0.10), then the fixed-effects model was used. Publication bias was estimated by Egger's test (p<0.05 was considered representative of statistically significant publication bias) (Egger et al., 1997) and visual observation of funnel plot (Begg and Mazumdar, 1994) , p<0.05 or an asymmetric plot suggested possible publication bias. All statistical manipulations were undertaken using the program STATA version 12.0 (Stata Corporation, College Station, TX), a p value <0.05 was considered statistically significant, except where otherwise specified.
Results
Study characteristics
According to the inclusion criteria defined above, a total of 11 publications (Ellis et al., 2008; Phang et al., 2008; Zenz et al., 2008; Chen et al., 2009; Do et al., 2009; Xiong et al., 2009; Phillips et al., 2010; Dong et al., 2012; Ebid et al., 2012; Chen et al., 2013; Liu et al., 2013) containing 12 case-control studies with 2362 cases and 5562 controls concerning MDM2 T309G polymorphism with respect to leukemia were included in the metaanalysis. The studies were published between 2008 and 2013, all of these studies were written in English. The study characteristics of the included in the meta-analysis were presented in Table 1 , distribution of MDM2 T309G :http://dx.doi.org/10.7314/APJCP.2014.15.16.6767 Association between MDM2 T309G Polymorphism and Leukemia Risk: a Meta-analysis genotypes among leukemia cases and controls were shown in Table 2 . The 12 case-control studies consist of 6 Caucasians and 6 Asians, and 12 case-control studies comprised 2 ALL studies, 6 AML studies, 2 CLL studies and 2 CML studies. (Figure 2 ). In the sub-group analysis according to type of leukemia, significantly association was found (Figure 3 and Figure 4 ).
Quantitative synthesis of data
Heterogeneity analysis and sensitive analysis
As shown in Table 3 , there was significant betweenstudy heterogeneity in overall populations. Therefore, the random effect model was utilized to evaluate the relationship of MDM2 T309G polymorphism and leukemia risk. Since the substantial heterogeneity among these studies in overall comparisons, we assessed the source of heterogeneity by ethnicity, subsequently, heterogeneity disappeared in subgroups of Caucasian subjects (I 2 <50%, p>0.1).
We selected two articles whose genetic distributions in controls exhibited significant failure to follow HWE, but the deviation might contribute to any bias, and the significances of data in all genetic models were also not statistically changed. We also evaluate the stability of the overall results by sequential remove individual studies.
The result of sensitive analysis shows that no single study could influence the overall results qualitative (data not shown), indicating robustness and reliability of our results.
Publication bias
Both Begg's funnel plot and Egger's test were performed to assess the publication bias. The shape of the funnel plot did not suggest any evidence of obvious asymmetry ( Figure 5) . Similarly, the results revealed the absence of publication bias (p>0.05, data not shown).
Discussion
Leukemia is a type of malignant clonal hematopoietic stem cell disorders with a bad prognosis (Estey, 2001 ). According to the speed of onset, leukemia can be divided into acute leukemia and chronic leukemia (Vardiman et al., 2009 ). Acute leukaemia is an extremely heterogeneous malignant disease, and acute leukemia can be subdivided into acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML) according to cytogenic analysis (Vardiman et al., 2009) . Acute lymphoblastic leukemia (ALL) is more common in children, which comprises over 80% of all the acute leukemia. It is estimated that approximately 33.6 in every 1, 000, 000 children under 15 years old will develop ALL. While acute myeloid leukemia (AML) is the most common form of acute leukemia in adults as well as in children (Gamazon et al., 2013) , it causing immature myeloid precursors to accumulate, and resulting in an estimated 13, 330 cases and an estimated 8, 950 deaths in the United States in 2010 (Wang et al., 2013) . But unfortunately, the exact pathological mechanism of leukemia is still unclear recently. There are several studies published to assess the associations of MDM2 T309G polymorphism with the risk of leukemia, but they reported contradictory results and failed to confirm a strong and consistent association (Ellis et al., 2008; Phang et al., 2008; Zenz et al., 2008; Chen et al., 2009; Do et al., 2009; Xiong et al., 2009; Phillips et al., 2010; Dong et al., 2012; Ebid et al., 2012; Chen et al., 2013; Liu et al., 2013) . In order to evaluate the evidence between the associations of MDM2 T309G polymorphisms with leukemia risk, we conducted this meta-analysis.
Total of 11 publications (Ellis et al., 2008; Phang et al., 2008; Zenz et al., 2008; Chen et al., 2009; Do et al., 2009; Xiong et al., 2009; Phillips et al., 2010; Dong et al., 2012; Ebid et al., 2012; Chen et al., 2013; Liu et al., 2013) containing 12 case-control studies with 7924 individuals (2362 cases and 5562 controls) were included in our meta-analysis. The results showed that MDM2 T309G polymorphism was associated with increased risk of leukemia (Table 3 ). There were several reports suggest that the polymorphism of MDM2 T309G is associated with the risk of sarcoma and endometrial, hepatocellular, colorectal cancer, breast cancer, malignant bone tumor, osteosarcoma and gastric cancer Gao et al., 2014; Tang et al., 2014; Wang et al., 2014) . By contrast, there was a study reported that the MDM2 SNP309 G allele probably acts as an important HNSCC protective factor in Caucasians, no association exists in Asians (Liu et al., 2011) . This shows that MDM2 T309G variation might play different roles in different cancers.
Ebid's article entitled "MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia" hat published on APJCP in 2012, the article through analysis 77 diagnosed AML patients by PCR experiments, the results is high reliability, and the electrophoresis is intuitive, the results of Ebid's article suggested that MDM2 T309G polymorphism might be genetic susceptibility factors in the pathogenesis of AML, which consistent with our conclusions.
Subgroup analysis based on ethnicity indicated that MDM2 T309G polymorphism was a risk factor for leukemia in Asians but not for Caucasians, suggest ethnic different in the occurrence of leukemia is exist, gene polymorphisms could result in ethnic-specific susceptibility to leukemia. In addition, environmental factors like birthplace and socioeconomic status may play important roles in leukemogenesis, this is the possible reason of exist of racial disparities.
The heterogeneity plays an important role in a metaanalysis. Significant heterogeneity was observed in our meta-analysis in overall populations. To finding the source of heterogeneity, we used subgroup analysis. In the subgroup analysis by ethnicity, we found heterogeneity was disappeared in Caucasians. This may explain by that different ethnicity has different life style, exposed to different risk factors and the levels of exposed to risk factors is also differ, this may cause the heterogeneity.
Publication bias is also an important aspect which may have a negative effect on a meta-analysis. In our metaanalysis, both Funnel plot and Egger's test were used to test the publication bias of the included studies. As a result, both the shape of funnel plot and statistical results show no obvious publication bias, this suggests that the publication bias have little effect on the results in our study and the results of our meta-analysis are relatively stable.
There are some limitations of this meta-analysis should be pointed. First, the number of studies and the number of samples included in the meta-analysis were relatively small. Secondly, only published and English studies were included in this work, thus, publication and potential English language bias may have occurred. Thirdly, subgroup analyses according to age, gender, radiation exposure, histological types and other elements haven't been performed in the study because no sufficient relevant data available in the primary studies. So, more studies with larger sample size and providing detailed information should be performed to assess the effect of MDM2 T309G polymorphism on leukemia risk. 
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In summary, the results of our meta-analysis suggest that the MDM2 T309G polymorphism can increase the risk of leukemia, especially among Asian populations. Considering the limited sample size and ethnicities included in the meta-analysis, further large scaled and well-designed studies are needed to confirm our results.
